Document Detail


Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
MedLine Citation:
PMID:  18461068     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
With improved treatment strategies and prognosis for patients with Hodgkin lymphoma (HL), interest has increasingly focused on high-risk groups. These groups include a small proportion of patients who experience relapse or who have primary refractory disease despite state-of-the-art treatment. Although many research efforts have been made in this field, specific biological markers that reliably predict unfavorable outcome during first-line treatment are lacking. Recent analyses in HL and other malignancies, however, have demonstrated an important impact of patient-related factors, such as individual differences in hematologic toxicity and drug metabolism, on disease outcome. A different cytochrome enzyme status and slower drug clearance in female patients, resulting in higher systemic toxicity and effectiveness of treatment, indicate that sex-specific aspects are important. In this Review, we discuss the current data on hematotoxicity among male and female patients with HL and other malignancies. In addition, we highlight the potential causes of hematotoxicity and its impact on treatment outcome and the role of future strategies.
Authors:
Beate Klimm; Andreas Engert
Related Documents :
8649058 - Hodgkin's disease: from basic science to clinical application.
7296488 - Second malignant neoplasms in patients treated for hodgkin's disease with radiotherapy ...
10400368 - Hodgkin's disease and non-hodgkin's lymphoma.
301608 - Impaired humoral immunity in treated hodgkin's disease.
6766788 - Clinical experience with irradiation of inflammatory carcinoma of the breast with and w...
17014898 - The prognostic significance of positive peritoneal cytology and adnexal/serosal metasta...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-05-06
Journal Detail:
Title:  Nature clinical practice. Oncology     Volume:  5     ISSN:  1743-4262     ISO Abbreviation:  -     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-30     Completed Date:  2008-08-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101226509     Medline TA:  Nat Clin Pract Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  316-23     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*
Female
Hematologic Diseases / chemically induced*
Hodgkin Disease / drug therapy*,  genetics
Humans
Male
Sex Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.
Next Document:  Portal vein thrombosis as the first sign of nephrotic syndrome.